Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

Carlos Romo, M.D., is a neuro-oncologist in Baltimore, Maryland. Dr. Romo specializes in the diagnosis and treatment of brain tumors, including glioblastoma, astrocytomas, oligodendrogliomas, neurofibromas, and schwannomas among others. Dr. Romo earned his medical degree from the School of Medicine and Health Sciences at Tecnológico de Monterrey in Mexico and completed his Neurology residency at the University of Arkansas for Medical Sciences, where he served as chief resident. He then completed a Neuro-oncology clinical and research fellowship in a joint program between The Johns Hopkins University and the National Institutes of Health. Dr. Romo additionally trained as a clinical pharmacology fellow at The Johns Hopkins University and completed training on clinical cancer research at the University of Texas MD Anderson Cancer Center. In his research, Dr. Romo studies drug pharmacokinetics and the blood-brain barrier, and investigates better ways to reach tumors in the central nervous system. Dr. Romo also studies treatments for patient with neurofibromatosis. In addition to patient care and research, Dr. Romo teaches and mentors medical and undergraduate students to help develop a future generation of neurologists. Dr. Romo is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Schwannomatosis, and Astrocytoma.

Dr. Christine Pratilas is a pediatric medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and Associate Professor of Oncology, Pediatrics & Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine. She joined the Hopkins pediatric sarcoma team in 2014. Dr. Pratilas received her undergraduate degree in Biology from Drew University in New Jersey and her medical degree from UMDNJ - Robert Wood Johnson Medical School (now Rutgers University), where she also completed her internship and residency from 1999 to 2002. From 2002 to 2005 she was a fellow in hematology and oncology in the Memorial Sloan Kettering Cancer Center (MSKCC) Department of Pediatrics, and in the Department of Pediatric Hematology and Oncology at New York Weill Cornell Medical Center. She was a postdoctoral research fellow in Dr. Neal Rosen’s Molecular Oncogenesis Laboratory at MSKCC. From 2006 to 2014 she was attending in Pediatric Oncology at MSKCC, specializing in developmental therapeutics & sarcoma. She has been the director of the pediatric sarcoma program at Hopkins since 2018. Dr. Pratilas focuses her research on cancer-associated pathways and signal transduction, which involves figuring out how a cell’s internal molecular pathways work, and how those pathways can be molecularly controlled. This knowledge is the basis for developing promising new molecularly targeted cancer therapies, which is the focus of Dr. Pratilas’s research. Among her important scientific contributions is advancing our understanding of how certain proteins that can be mutated in cancer, known as RAF kinases (specifically BRAF), affect a cancer cell’s behavior. The research in Dr. Pratilas' laboratory is focused on RAS signal transduction pathways, concentrating on pediatric sarcomas such as rhabdomyosarcoma and malignant peripheral nerve sheath tumors, in order to develop novel therapeutics for children with these tumors. Dr. Pratilas is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Adult Soft Tissue Sarcoma, and Osteotomy.

Brigitte Widemann is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Widemann is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Adult Soft Tissue Sarcoma, and Thyroidectomy.

Dr. Allan Belzberg is a neurosurgeon specializing in surgery of the peripheral nervous system. As Director of Peripheral Nerve Surgery at Johns Hopkins in Baltimore, he treats tumors including schwannoma, neurofibroma and nerve sheath tumor. Dr. Belzberg performs surgical repair of nerve damage caused by trauma as well as neurosurgery on carpal tunnel, peroneal nerve and other peripheral nerve conditions. Dr. Belzberg also directs the Brachial Plexus and Peripheral Nerve Clinic at the Kennedy Krieger Institute and co-directs the Neurosurgery Pain Research Institute at Johns Hopkins Hospital. Dr. Belzberg currently sees patients at the Johns Hopkins Outpatient Center located in Baltimore on Wednesdays and the Green Spring Station location on Fridays. Dr. Belzberg is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Schwannomatosis, Neurofibromatosis, Thoracic Outlet Syndrome, Osteotomy, and Rhizotomy.

Dr. Ahlawat earned a Bachelor of Arts with magna cum laude at New York University. She completed both her Medical Degree as well as residency training in diagnostic radiology at Rutgers University’s Robert Wood Johnson Medical School in New Brunswick, NJ. Dr. Ahlawat completed her Pediatric Radiology Fellowship at the Children’s National Medical Center in Washington, DC and went on to Johns Hopkins University in Baltimore, MD to do a Fellowship in musculoskeletal radiology. After completion of her fellowship, Dr. Ahlawat joined as faculty in the Diagnostic Division of the department of Radiology at the Johns Hopkins University. Currently, she is an Assistant Professor in the Johns Hopkins University Department of Radiology and Radiological Science. Dr. Ahlawat’s expertise is Diagnostic Radiology with additional training in pediatric and musculoskeletal radiology. Dr. Ahlawat specializes in high resolution magnetic resonance (MR) imaging of peripheral nerves, specifically detection and characterization of peripheral nerve injury; MR imaging of peripheral nerve tumors and peripheral nerve tumor syndromes; whole body MR imaging in the setting of peripheral nerve tumor syndromes; and advanced MR techniques such as quantitative diffusion weighted imaging and apparent diffusion coefficient mapping in characterization of bone and soft tissue tumors. Dr. Shivani Ahlawat also serves as the Director of the Musculoskeletal Fellowship Program. Dr. Ahlawat is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Schwannomatosis, Neurofibromatosis, Neurofibromatosis Type 1 (NF1), and Neurofibromatosis Type 2 (NF2).

Dr. Laura M. Fayad serves as the Chief of Musculoskeletal Imaging. She is a Professor in the Johns Hopkins University Department of Radiology and Radiological Science, Department of Oncology, and Department of Orthopaedic Surgery. Dr. Fayad is also the Director of the Translational Research Program in the Department of Radiology. Dr. Fayad earned a Bachelor of Science at the Massachusetts Institute of Technology, a Master of Science at Stanford University, and M.D. C.M. degrees at the McGill University Faculty of Medicine. She completed residency training at Columbia University and MRI Fellowship at Thomas Jefferson University. She specializes in diagnostic and interventional musculoskeletal radiology. In addition to routine sports medicine and spine applications, Dr. Fayad protocols and interprets specialized examinations in the areas of peripheral nerve imaging, tumor imaging, and rheumatology. Her primary area of research focuses on novel imaging techniques for musculoskeletal tumors, with her work including well over 100 publications that have been cited more than 1,500 times. Dr. Fayad is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Schwannomatosis, Neurofibromatosis, Liposarcoma, and Neurofibromatosis Type 2 (NF2).

Nurse practitioner Shannon Langmead specializes in neurofibromatosis and is the clinic coordinator of the Johns Hopkins Comprehensive Neurofibromatosis (NF) Center. She evaluates and manages patients with NF1, NF2 and Schwannomatosis. Her special interests include pain management and developing social support networks for patients who have NF. Shannon earned bachelor’s degrees in Spanish and nursing from Saint Francis University in Pennsylvania and Villa Julie College in Maryland, and completed her master’s degree in nursing at The Johns Hopkins University School of Nursing. She has worked as a bedside nurse in neurology and neurosurgery at The Johns Hopkins Hospital and as a part-time clinical faculty member for The Johns Hopkins University School of Nursing. Ms. Langmead is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Neurofibromatosis, RASopathies, Neurofibromatosis Type 1 (NF1), and Legius Syndrome.

Aerang Kim is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Rhabdomyosarcoma.

Constantine Stratakis is a Medical Genetics specialist and a Gastroenterologist in Bethesda, Maryland. Dr. Stratakis is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Cushing's disease, Neuroendocrine Tumor, Gastrointestinal Stromal Tumor, Orchiectomy, and Hormone Replacement Therapy (HRT).

Chad Gordon is a Plastic Surgeon in Baltimore, Maryland. Dr. Gordon is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Neurofibromatosis, Legius Syndrome, Neurofibromatosis Type 1 (NF1), Osteotomy, and Bone Graft.

Prashant Chittiboina is a Neurosurgery provider in Bethesda, Maryland. Dr. Chittiboina is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Cushing's disease, Hemangioblastoma, Von Hippel-Lindau (VHL) Syndrome, Pituitary Tumor, and Laminectomy.

Thomas Bosley is an Ophthalmologist and a Neurologist in Baltimore, Maryland. Dr. Bosley is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Duane-Radial Ray Syndrome, Sulfite Oxidase Deficiency, Isolated Duane Retraction Syndrome, and Kearns-Sayre Syndrome.

Jignesh Tailor is a General Surgeon and a Neurosurgery provider in Baltimore, Maryland. Dr. Tailor is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Choroid Plexus Cyst, Hydrocephalus, Hydrocephalus due to Congenital Stenosis of Aqueduct of Sylvius, Rhizotomy, and Awake Craniotomy.

Scott Paul is a Physiatrist in Silver Spring, Maryland. Dr. Paul is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Neurofibromatosis, Poland Syndrome, Moebius Syndrome, and Kienbock's Disease.

Lindy Zhang is a Pediatric Hematologist Oncology provider in Middle River, Maryland. Dr. Zhang has been practicing medicine for over 10 years and is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Adult Soft Tissue Sarcoma.

Archis Bhandarkar is a Neurosurgery provider in Baltimore, Maryland. Dr. Bhandarkar is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Schwannoma, Osteotomy, and Craniectomy.

Paul Sponseller is an Orthopedics provider in Baltimore, Maryland. Dr. Sponseller is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Scoliosis, Adolescent Idiopathic Scoliosis, Spastic Diplegia Infantile Type, Spinal Fusion, and Osteotomy. Dr. Sponseller is currently accepting new patients.

Dr. Kathryn Lemberg is an Assistant Professor of Oncology and Pediatrics at the Sidney Kimmel Comprehensive Cancer Center. Her research, conducted with Johns Hopkins Drug Discovery, focuses on tumor metabolism and the development of new metabolic inhibitors to treat cancer. She has investigated novel glutamine antagonists in preclinical models of RAS-driven solid tumors. She is also interested in the effects of tumor metabolism on patient growth and development. Dr. Lemberg completed pediatrics residency training at Johns Hopkins and pediatric hematology-oncology fellowship training in the joint Johns Hopkins/National Cancer Institute program. She received her M.D. and Ph.D. degrees from the Medical Scientist Training Program at Columbia University in New York, where her graduate research focused on ferroptosis, a novel oxidative cell death in cancer models. Dr. Lemberg sees pediatric and young adult sarcoma patients as part of the sarcoma team and has additional clinical focus on neurofibromatosis type I related solid tumors. Dr. Lemberg is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Adult Soft Tissue Sarcoma.

Chetan Bettegowda is the director of the Johns Hopkins Department of Neurosurgery. He offers comprehensive treatments for adult patients with benign and malignant brain tumors, specializing in the treatment of patients with primary brain tumors such as gliomas, meningiomas and pituitary tumors. He performs both open surgery and stereotactic radiosurgery for patients with metastatic tumors to the brain, and also provides stereotactic radiosurgery for other neurological disorders, including spinal tumors, trigeminal neuralgia and skull-base tumors. Dr. Bettegowda is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Trigeminal Neuralgia, Astrocytoma, Glioblastoma, Rhizotomy, and Microvascular Decompression.